PDF(Pubmed)
Abstract：
UNASSIGNED: Patients with intermediate-risk prostate cancer are faced with the decision of whether to undergo radical treatment. Decision-making aids, such as Predict Prostate, can empower both clinicians and patients to make treatment decisions with personalised information, but their impact on multi-disciplinary team (MDT) decision-making and uptake of radical treatment remains unknown.
UNASSIGNED: The objective of this study is to assess the utilisation and utility of Predict Prostate in informing treatment decisions for patients with intermediate-risk prostate cancer.
UNASSIGNED: A retrospective cohort study was conducted in Cambridge University Hospitals (CUH) of patients referred to the prostate cancer specialist multi-disciplinary team (pcSMDT) and robotic prostatectomy clinic (ROPD) between September 2019 and August 2021 for consideration of radical prostatectomy (RARP). Data on patient characteristics, use of PredictProstate and management decisions were collected from the Epic electronic medical record (EMR) of 839 patients, of whom 386 had intermediate-risk prostate cancer.
UNASSIGNED: The use of Predict Prostate at the pcSMDT increased in the second half of the study period (34.5% vs. 23.8%, p < 0.001). The use of Predict Prostate was associated with an increased likelihood of attending ROPD for men with CPG2 prostate cancer (OR = 2.155, 95% CI = 1.158-4.013, p = 0.015) but a reduced likelihood of proceeding with RARP for men with CPG2 (OR = 0.397, 95% CI = 0.209-0.753, p = 0.005) and CPG3 (OR = 0.305, 95% CI = 0.108-0.861, p = 0.025) prostate cancer.
UNASSIGNED: Our study showed that the use of Predict Prostate for patients with intermediate-risk prostate cancer is associated with increased attendance at specialist surgical clinic and a reduced chance of undergoing radical prostate surgery.
UNASSIGNED: The objective of this study is to assess the utilisation and utility of Predict Prostate in informing treatment decisions for patients with intermediate-risk prostate cancer.
UNASSIGNED: A retrospective cohort study was conducted in Cambridge University Hospitals (CUH) of patients referred to the prostate cancer specialist multi-disciplinary team (pcSMDT) and robotic prostatectomy clinic (ROPD) between September 2019 and August 2021 for consideration of radical prostatectomy (RARP). Data on patient characteristics, use of PredictProstate and management decisions were collected from the Epic electronic medical record (EMR) of 839 patients, of whom 386 had intermediate-risk prostate cancer.
UNASSIGNED: The use of Predict Prostate at the pcSMDT increased in the second half of the study period (34.5% vs. 23.8%, p < 0.001). The use of Predict Prostate was associated with an increased likelihood of attending ROPD for men with CPG2 prostate cancer (OR = 2.155, 95% CI = 1.158-4.013, p = 0.015) but a reduced likelihood of proceeding with RARP for men with CPG2 (OR = 0.397, 95% CI = 0.209-0.753, p = 0.005) and CPG3 (OR = 0.305, 95% CI = 0.108-0.861, p = 0.025) prostate cancer.
UNASSIGNED: Our study showed that the use of Predict Prostate for patients with intermediate-risk prostate cancer is associated with increased attendance at specialist surgical clinic and a reduced chance of undergoing radical prostate surgery.
摘要：
■中危前列腺癌患者面临是否接受根治性治疗的决定。决策辅助工具，比如预测前列腺，可以授权临床医生和患者使用个性化信息做出治疗决策，但它们对多学科团队(MDT)决策和接受根治性治疗的影响仍然未知.
■本研究的目的是评估预测前列腺在中危前列腺癌患者的治疗决策中的应用和效用。
■在2019年9月至2021年8月期间，剑桥大学医院（CUH）对转诊至前列腺癌专家多学科团队（pcSMDT）和机器人前列腺切除术诊所（ROPD）的患者进行了一项回顾性队列研究，考虑进行根治性前列腺切除术（RARP）。关于患者特征的数据，从839例患者的Epic电子病历（EMR）中收集了前列腺的使用和管理决策，其中386人患有中危前列腺癌。
■在研究期间的下半年，pcSMDT中预测前列腺的使用增加了（34.5％vs.23.8%,p<0.001)。预测前列腺的使用与CPG2前列腺癌男性参加ROPD的可能性增加相关（OR=2.155，95％CI=1.158-4.013，p=0.015），但对于CPG2（OR=0.397，95％CI=0.209-0.753，p=0.005）和CPG3（OR=0.108，95％CI=0.108-0.8305）前列腺癌的可能性降低。
■我们的研究表明，中危前列腺癌患者使用预测前列腺与增加专科外科诊所的出勤率和减少接受根治性前列腺手术的机会有关。
■本研究的目的是评估预测前列腺在中危前列腺癌患者的治疗决策中的应用和效用。
■在2019年9月至2021年8月期间，剑桥大学医院（CUH）对转诊至前列腺癌专家多学科团队（pcSMDT）和机器人前列腺切除术诊所（ROPD）的患者进行了一项回顾性队列研究，考虑进行根治性前列腺切除术（RARP）。关于患者特征的数据，从839例患者的Epic电子病历（EMR）中收集了前列腺的使用和管理决策，其中386人患有中危前列腺癌。
■在研究期间的下半年，pcSMDT中预测前列腺的使用增加了（34.5％vs.23.8%,p<0.001)。预测前列腺的使用与CPG2前列腺癌男性参加ROPD的可能性增加相关（OR=2.155，95％CI=1.158-4.013，p=0.015），但对于CPG2（OR=0.397，95％CI=0.209-0.753，p=0.005）和CPG3（OR=0.108，95％CI=0.108-0.8305）前列腺癌的可能性降低。
■我们的研究表明，中危前列腺癌患者使用预测前列腺与增加专科外科诊所的出勤率和减少接受根治性前列腺手术的机会有关。
